Literature DB >> 11259614

Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states.

M A Cox1, C H Jenh, W Gonsiorek, J Fine, S K Narula, P J Zavodny, R W Hipkin.   

Abstract

The human CXC chemokines IP-10 (10-kDa interferon-inducible protein), MIG (monokine induced by human interferon-gamma), and I-TAC (interferon-inducible T cell alpha chemoattractant) attract lymphocytes through activation of CXCR3. In the studies presented here, we examined interaction of these chemokines with human CXCR3 expressed in recombinant cells and human peripheral blood lymphocytes (PBL). IP-10, MIG, and I-TAC were agonists in stimulating [(35)S]GTP gamma S binding in recombinant cell and PBL membranes but had no effect in the absence of hCXCR3 expression. (125)I-IP-10 and (125)I-I-TAC bound hCXCR3 with high affinity, although the (125)I-I-TAC B(max) value in saturation bindings was 7- to 13-fold higher than that measured with (125)I-IP-10. Coincubation with unlabeled chemokines decreased (125)I-IP-10 binding with a single discernible affinity. However, with (125)I-I-TAC, competition with IP-10 or MIG was incomplete, and multiple binding affinities were evident. Moreover, in contrast to I-TAC, IP-10 and MIG binding IC(50) values did not increase predictably with increased (125)I-I-TAC concentration in competition bindings, suggesting that these chemokines are noncompetitive (i.e., allotopic) ligands. Uncoupling of hCXCR3 eliminated (125)I-IP-10 binding but only decreased (125)I-I-TAC binding 30 to 80%, indicating that unlike IP-10, I-TAC binds with high affinity to uncoupled (R) and coupled (R*) hCXCR3. To examine chemokine binding to R*, we tested the effect of anti-hCXCR3 antibody on I-TAC- and IP-10-stimulated [(35)S]GTP gamma S binding. The antibody attenuated [(35)S]GTP gamma S binding in response to IP-10 but not to I-TAC, suggesting that the two chemokines bind differently to R*. Moreover, increased occupancy of R* with a >75-fold increase in (125)I -IP-10 concentration did not increase the I-TAC binding IC(50) value, and I-TAC increased the dissociation rate of (125)I-IP-10. From these data, we conclude that the binding of IP-10 and I-TAC to the R* state of hCXCR3 is allotopic.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11259614     DOI: 10.1124/mol.59.4.707

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  42 in total

Review 1.  Chemokines in Wound Healing and as Potential Therapeutic Targets for Reducing Cutaneous Scarring.

Authors:  Peter Adam Rees; Nicholas Stuart Greaves; Mohamed Baguneid; Ardeshir Bayat
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-11-01       Impact factor: 4.730

Review 2.  Oligomers of D2 dopamine receptors: evidence from ligand binding.

Authors:  Philip G Strange
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

3.  Biased agonism as a mechanism for differential signaling by chemokine receptors.

Authors:  Sudarshan Rajagopal; Daniel L Bassoni; James J Campbell; Norma P Gerard; Craig Gerard; Tom S Wehrman
Journal:  J Biol Chem       Date:  2013-10-21       Impact factor: 5.157

Review 4.  Useful biomarkers for assessment of hepatitis C virus infection-associated autoimmune disorders.

Authors:  Deng-Ho Yang; Ling-Jun Ho; Jenn-Haung Lai
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

5.  Biased agonists of the chemokine receptor CXCR3 differentially control chemotaxis and inflammation.

Authors:  Jeffrey S Smith; Lowell T Nicholson; Jutamas Suwanpradid; Rachel A Glenn; Nicole M Knape; Priya Alagesan; Jaimee N Gundry; Thomas S Wehrman; Amber Reck Atwater; Michael D Gunn; Amanda S MacLeod; Sudarshan Rajagopal
Journal:  Sci Signal       Date:  2018-11-06       Impact factor: 8.192

6.  Pharmacological characterization of a small-molecule agonist for the chemokine receptor CXCR3.

Authors:  D J Scholten; M Canals; M Wijtmans; S de Munnik; P Nguyen; D Verzijl; I J P de Esch; H F Vischer; M J Smit; R Leurs
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

7.  Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1.

Authors:  Julie M Strizki; Cecile Tremblay; Serena Xu; Lisa Wojcik; Nicole Wagner; Waldemar Gonsiorek; R William Hipkin; Chuan-Chu Chou; Catherine Pugliese-Sivo; Yushi Xiao; Jayaram R Tagat; Kathleen Cox; Tony Priestley; Steve Sorota; Wei Huang; Martin Hirsch; Gregory R Reyes; Bahige M Baroudy
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

Review 8.  CXCR3 ligands: redundant, collaborative and antagonistic functions.

Authors:  Joanna R Groom; Andrew D Luster
Journal:  Immunol Cell Biol       Date:  2011-01-11       Impact factor: 5.126

9.  Maternal serum concentrations of the chemokine CXCL10/IP-10 are elevated in acute pyelonephritis during pregnancy.

Authors:  Francesca Gotsch; Roberto Romero; Jimmy Espinoza; Juan Pedro Kusanovic; Shali Mazaki-Tovi; Offer Erez; Nandor Gabor Than; Samuel Edwin; Moshe Mazor; Bo Hyan Yoon; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2007-10

10.  Pharmacological characterization of human S1P4 using a novel radioligand, [4,5-3H]-dihydrosphingosine-1-phosphate.

Authors:  James Fossetta; Gregory Deno; Waldemar Gonsiorek; Xuedong Fan; Brian Lavey; Pradip Das; Charles Lunn; Paul J Zavodny; Daniel Lundell; R William Hipkin
Journal:  Br J Pharmacol       Date:  2004-06-14       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.